Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P31994
UPID:
FCG2B_HUMAN
Alternative names:
CDw32; Fc-gamma RII-b
Alternative UPACC:
P31994; A6H8N3; O95649; Q53X85; Q5VXA9; Q8NIA1
Background:
The Low affinity immunoglobulin gamma Fc region receptor II-b, also known as CDw32 and Fc-gamma RII-b, plays a crucial role in the immune system. It acts as a receptor for the Fc region of complexed or aggregated immunoglobulins gamma, engaging in various effector and regulatory functions including phagocytosis of immune complexes and modulation of antibody production by B-cells. Its activity influences the modulation of cell activation states, impacting B-cell, T-cell, and Fc receptor-mediated responses.
Therapeutic significance:
Given its involvement in systemic lupus erythematosus, a disorder characterized by autoimmune system failure affecting multiple organs, the receptor presents a promising target for therapeutic intervention. Understanding the role of Low affinity immunoglobulin gamma Fc region receptor II-b could open doors to potential therapeutic strategies, offering hope for improved management of this complex disease.